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Key Points
• In newly diagnosed ITP,
addition of rituximab to
dexamethasone yields higher
sustained response rates
than dexamethasone alone.
In this study, we report the results from the largest cohort to date of newly diagnosed
adult immune thrombocytopenia patients randomized to treatment with dexamethasone
alone or in combination with rituximab. Eligible were patients with platelet counts
£253109/L or £503109/L with bleeding symptoms. A total of 133 patients were randomly
assigned to either dexamethasone 40 mg/day for 4 days (n 5 71) or in combination with
rituximab 375 mg/m2 weekly for 4 weeks (n 5 62). Patients were allowed supplemental
dexamethasone every 1 to 4 weeks for up to 6 cycles. Our primary end point, sustained
response (ie, platelets ‡503109/L) at 6 months follow-up, was reached in 58% of patients
in the rituximab1 dexamethasone group vs 37% in the dexamethasone group (P5 .02). The median follow-up time was 922 days. We
found longer time to relapse (P 5 .03) and longer time to rescue treatment (P 5 .007) in the rituximab 1 dexamethasone group. There
was an increased incidence of grade 3 to 4 adverse events in the rituximab 1 dexamethasone group (P 5 .04). In conclusion,
rituximab 1 dexamethasone induced higher response rates and longer time to relapse than dexamethasone alone. This study is
registered at http://clinicaltrials.gov as NCT00909077. (Blood. 2013;121(11):1976-1981)
Introduction
Primary immune thrombocytopenia (ITP) is characterized by
immune-mediated peripheral platelet destruction and impaired
platelet production in the bone marrow1,2 with consequent increased
risk of bleeding.3 Recommended ﬁrst-line treatment of symptomatic
ITP is glucocorticoids, but the majority of adult patients relapse
within the ﬁrst year of treatment and require additional therapy
including splenectomy.4
Rituximab (RTX) is recommended as a second-line treatment
of ITP,4 and several studies have shown that RTX induces an
initial response in up to 60% of patients with refractory ITP.5
However, the few studies evaluating long-term effects of RTX in
refractory ITP have shown that sustained response rates are in the
range of 20% to 35%, especially in patients with a longer duration
of ITP.6,7
Only 2 previous studies have investigated the role of RTX in
ﬁrst-line treatment of newly diagnosed ITP. Zaja et al reported
higher sustained response rates after 6 months of treatment with
dexamethasone (DXM) and RTX vs DXM in patients with newly
diagnosed ITP.8 Arnold et al recently reported the results of a pilot
study of RTX vs placebo as adjuvant to standard-of-care treatment
in a mixed cohort of newly diagnosed and relapsed ITP patients
with no difference in platelet counts after 6 months in the 2
groups.9 In this study, we present the results of the largest cohort to
date of newly diagnosed ITP patients treated with RTX1DXM vs
DXM alone with up to 4 years of follow-up.
Methods
Study design
We conducted a randomized open-label phase 3 trial in 9 Danish departments
of hematology. The study was initiated in 2006 and results were analyzed in
November 2011. The study is closed for inclusion, and a ﬁnal report on
follow-up data is expected in 2015.
Patients
Eligible patients were newly diagnosed adult patients>18 years of age with
conﬁrmed ITP and platelet counts <25 3 109/L or ITP with platelet counts
<50 3 109/L and concomitant bleeding symptoms. The clinical criteria for
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the diagnosis of ITP were: (1) isolated thrombocytopenia with platelet count
,100 3 109/L, (2) normal bone marrow biopsy with a normal or increased
number of megakaryocytes, (3) normal spleen size assessed by ultrasonog-
raphy, (4) exclusion of secondary immune- or drug-induced thrombocyto-
penias, (5) exclusion of virally induced thrombocytopenia, and (6) normal
levels of thyroid-stimulating hormone. Fertile women were included only if
adequate contraceptives had been used for a minimum of 3 months before
enrollment. Patients were allowed to have received oral prednisolone for up
to 1 week before enrollment. Exclusion criteria were low performance status
(>2 using the World Health Organization score system), previous therapy
with RTX or therapy with other immunomodulating agents within 1 month
of enrollment, serious comorbidities, pregnancy or lactation, contraindica-
tions for RTX (eg, anti-murine antibodies), or seropositive tests for human
immune deﬁciency virus, hepatitis B, hepatitis C, cytomegalovirus, Epstein-
Barr virus, anticardiolipid antibodies, or antinuclear antibodies. A bone
marrow biopsy and an abdominal ultrasonography were performed in all
patients to exclude hematological malignancy. The Committees on Bio-
medical Research Ethics of the Capital Region of Denmark approved the
protocol and all patients received oral and written information, according to
international guidelines, before giving written consent in accordance with the
Declaration of Helsinki.
Study procedures. Eligible patients were randomized 1:1 by use of
precoded envelopes to receive either a combination of RTX1DXM or
DXM as monotherapy. RTX was administered in a standardized dosage of
375 mg/m2,10 on day 2 of enrollment and thereafter once weekly for a total
of 4 weeks. Premedication included oral paracetamol (acetaminophen) and
intravenous antihistamine to reduce infusion-related discomfort. DXM was
administered orally in a dosage of 40 mg once daily for 4 consecutive days.
Patients were recruited between 2006 and 2011, and in 2009 an amendment
to the protocol allowed nonresponders (see “Enrollment and follow-up”)
in both arms to repeat the DXM treatment every 1 to 4 weeks for a total of
up to 6 treatment cycles.11 The choice of DXM vs prednisolone, both
recommended as ﬁrst-line treatments of ITP, was based on reports from
a study of 125 patients with newly diagnosed ITP treated with 1 cycle of
DXM in which 50% showed sustained response after 6 months.12 Safety
interim analyses after 2 years found that we could not reproduce the
response rates reported in the previous study (data not shown). Because
subsequent reports had shown a beneﬁt of repeated cycles of DXM,11 we
made an amendment to the protocol in 2009 allowing patients to receive up
to 6 cycles of DXM. Platelet counts were measured on all study visits and
immunoglobulin (Ig) levels were measured at baseline and after 3, 6, 12,
and 24 months.
Study outcomes. The primary end point was a sustained partial or
complete response at 6 months’ follow-up. Secondary end points included
time to relapse, time to rescue treatment, and rates of splenectomy. Complete
response was deﬁned as platelet count >100 3 109/L, partial response as
platelet count > 50 3 109/L, and no response as the absence of a rise in
platelet counts or a continued count of < 50 3 109/L. Patients withdrawn
from the study because of no response and patients receiving rescue
treatment before 6 months were deﬁned as nonresponders at 6 months. Initial
response was deﬁned as an increase in platelet counts of at least 303 109/L,
platelet counts .50 3 109/L on day 10, and no clinical bleeding. Relapse
was deﬁned as a drop in platelet count to <30 3 109/L following an initial
partial or complete response. Adverse events were recorded at all clinical
visits and graded according to the Common Toxicity Criteria version 2.0.
Statistical analysis
Differences in achieving complete or partial response between the 2 groups
and differences in adverse events were analyzed by the Fisher’s exact test.
Fraction of relapse-free patients, time to relapse, time to rescue treatment, and
rates of splenectomy were compared using the Kaplan-Meier method and log-
rank test. For descriptive statistics, we used the Mann-Whitney test, Wilcoxon
signed-rank test, and Fisher’s exact test. All P values were 2-sided, and P
values below .05 were considered signiﬁcant. IBM SPSS Statistics version
19.0.0 (2010, IBM, Somers, NY) or R Statistical Software version 2.14.1
(2011, R Foundation for Statistical Computing, Vienna, Austria) were used
for all analyses.
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Figure 1. Patient flowchart. AML, acute myeloid
leukemia; CLL, chronic lymphatic lymphoma; MDS,
myelodysplastic syndrome.
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Results
Enrollment and follow-up
Patients were enrolled in the study from its initiation between March
2006 and August 2011. In this period, 155 patients were included,
137 being subsequently randomized to receive RTX1DXM (n5 63,
no data available for 1 patient) or DXM alone (n 5 74, no data
available for 3 patients). The median time from screening to ran-
domization was 1 day (interquartile range [IQR] 0–3 days) in both
groups. The excluded 18 patients were identiﬁed as secondary ITP
(n5 15), withdrew consent (n5 1), or did not meet inclusion criteria
(n 5 2; 1 patient had a third relapse of ITP; 1 patient had received
intravenous immunoglobulin [IVIG] 1 week before enrollment)
(Figure 1). Baseline characteristics were balanced between the 2
groups, and no patients were splenectomized at time of inclusion
(Table 1). Non-ITP medications administered in .5% of patients
included antihypertensives, anti-diabetics, proton pump inhibitors,
cholesterol-lowering drugs, and pain medication. In the RTX1DXM
group, 19 patients (31%) were administered>2 cycles of DXM vs 31
patients (44%) in the DXM group, P 5 .09 (Table 1).
This is the ﬁrst report from a prospective cohort study; thus,
follow-up time varied within the groups with no differences between
the 2 groups (Table 1). Patients withdrawn from the study because of
no response and patients receiving rescue treatment before 6 months
(not including study-permitted additional cycles of dexamethasone)
were deﬁned as nonresponders for the duration of the study. Thus, 60
patients (97%) in the RTX1DXM group and 63 patients (89%) in the
DXM group had completed 6 months follow-up at the time of data
analyses. Three-years of follow-up were attained by 26 patients (42%)
in the RTX1DXM group and 25 patients (35%) in the DXM group.
In the RTX1DXM group, 8 patients were lost to follow-up
during the ﬁrst 3 years vs 6 patients in the DXM group. Patients were
lost to follow-up according to their own request (n 5 9) or of
unknown causes (n 5 5). Five patients in the RTX1 DXM group
were withdrawn early from the study vs 9 patients in the DXM group.
Reasons for early withdrawal were: complete remission (n 5 2);
pregnancy (n 5 2); unacceptable adverse events (n 5 3); newly
diagnosed comorbidities (n 5 3); patient deceased (n 5 4). Patients
with relapse before the time of withdrawal were counted as
nonresponders and included as events in the time-to-relapse and, if
relevant, time-to-rescue-treatment analyses. The patients withdrawn
because of adverse events or comorbidities and those deceased were
censored at their withdrawal but were considered nonresponders in
the intention-to-treat analyses. The 2 pregnant patients were censored
at time of withdrawal. The 2 patients withdrawn because of complete
remission were censored at their withdrawal; both had been included
in the study for more than 3 years.
Response rates
Sustained partial or complete response at 6 months’ follow-up was
achieved in 58% of patients in the RTX1DXM group and 37% of
patients in the DXMmonotherapy group (P5 .02). Study-permitted
supplemental cycles of DXMwere received by 5 responding patients
in the RTX1DXM group vs 10 responding patients in the DXM
group. In an intention-to-treat analysis, including patients either
dying or withdrawn because of adverse events, partial or complete
response was achieved in 57% of the patients in the RTX1DXM
group and 35% of the patients in the DXMmonotherapy group (P5
.01). In the RTX1DXM group, 11 of 26 nonresponding patients
(42%) had an initial response to therapy but relapsed after a median
(range) of 25 days (15 to 55 days). Accordingly, 18 of 45
nonresponding patients in the DXM group (40%) had an initial
response but relapsed after a median (range) of 32 days (13 to 139
days). Study-permitted supplemental cycles of DXM were admin-
istered in 14 of the 26 nonresponding patients in the RTX1DXM
group and in 21 of the 45 nonresponders in the DXM group.
At 12 months’ follow-up, sustained partial or complete response
was achieved in 53% of patients in the RTX1DXM group and 33%
patients in the DXM monotherapy group (P , .05). During a 3-year
observational period (RTX1DXM median 921 days [IQR 526-
1152]; DXM median 922 days [IQR 190-1126]), there was sig-
niﬁcantly longer time to relapse deﬁned as a drop in platelet counts
to,503 109/L following an initial, partial, or complete response in
the RTX1DXM group as compared with the DXM group (P5 .03,
Table 1. Baseline characteristics
Parameter
RTX1DXM
(n 5 62) DXM (n 5 71)
P value for
difference
between
groups
Age, median (IQR) 51 y (36-63) 58 y (41-70) .2
Females, n (%) 36 (58%) 34 (48%) .3
Baseline platelet count
3109/L, median (IQR)
13 (6-20) 14 (8-23) .4
Follow-up period in days,
median (IQR)
921 (526-1152) 922 (190-1126) .3
Dexamethasone cycles during treatment
1 cycle, no. of patients (%) 43 (69%) 40 (56%) .09
2-3 cycles, no. of
patients (%)
16 (26%) 22 (31%)
.4 cycles, no. of
patients (%)
3 (5%) 9 (13%)
IQR, interquartile range.
Figure 2. Kaplan-Meier plot of time to relapse in patients achieving initial,
partial, or complete response. Relapse was defined as a drop in platelet count to
#50 3 109/L following a complete response (platelet count $100 3 109/L), partial
response (platelet count$503 109/L), or initial response (increase in platelet counts
of at least 30 3 109/L, platelet counts .50 3 109/L on day 10 and no clinical
bleeding). No. at risk indicates number of patients with sustained complete or partial
response. P 5 .03.
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Figure 2). We also assessed the time to rescue treatment, deﬁned as
the time point when patients were administered rescue medicine for
ITP at the discretion of their hematologist. In patients who had
initially achieved a partial or complete response, median time to
rescue treatment in the DXM group was 7.4 months and median
time to rescue treatment was not reached in the RTX1DXM group
after 48 months. There was signiﬁcantly longer time to rescue
treatment in the RTX1DXM than in the DXM group (P 5 .007).
Median platelet count at time of rescue treatment was 15 3 109/L
(IQR 7-243 109/L).We found no differences in rates of splenectomy
in the 2 groups: 6 patients (10%) were splenectomized in the RTX1
DXM group vs 5 patients (7%) in the DXM group (P 5 .8).
Adverse events
Adverse events were, in general, mild and balanced between the 2
groups. Figure 3 shows adverse events reported by .5% of patients,
the most frequent being fatigue, dizziness, headache, epigastritis, and
anxiety. There was an overrepresentation of fever and muscle/joint
pains in the RTX1DXM group (17.6 vs 6.4%, P 5 .12) and of
anxiety in the DXMgroup (21.3 vs 3.9%,P5 .01). All adverse events
reported in this study have previously been described in the product
summaries of RTX andDXM. There were 16 reported serious adverse
events in the RTX1DXMgroup, including 1 death, as compared with
8 serious adverse events in the DXM group, including 3 deaths (P5
.04) (Table 2). None of the deaths were considered related to
treatment. In the RTX1DXM group, 5 patients were hospitalized
because of thrombocytopenia vs no patients in the DXM group. In
4 of the 5 patients, thrombocytopenia occurred within 2 to 4 weeks
after inclusion in the study. One of these patients did not receive
rescue treatment and platelet counts increased to .100 3 109 after
completion of rituximab therapy; the other 3 patients required long-
term prednisolone treatment and were thus considered nonresponders
in the protocol. The last patient was an 83-year-old nonresponder who
had received multiple rescue treatments including DXM, predniso-
lone, and IVIG. She was hospitalized with thrombocytopenia 2 years
after rituximab and treated with DXM and prednisolone. The
thrombocytopenias may be related to ITP or may be related to
treatment with RTX as this has previously been reported.13 One
patient in the RTX1DXM group and 2 patients in the DXM group
were withdrawn from the study because of adverse events.
Figure 3. Adverse events. Adverse events reported
by .5% of patients in either the rituximab 1 dexameth-
asone group or dexamethasone group. *P , .05.
BLOOD, 14 MARCH 2013 x VOLUME 121, NUMBER 11 RTX1DXM VS DXM ALONE IN NEWLY DIAGNOSED ITP 1979
For personal use only.on January 29, 2017. by guest  www.bloodjournal.orgFrom 
Ig serum levels
Pre- and posttreatment serum levels of IgG, IgM, and IgA were
available for 42 patients in the RTX1DXM group and 36 patients in
the DXM group. At 3 months’ follow-up, there was a signiﬁcant
decrease in IgG concentrations in the RTX1DXM group when
compared with baseline values (median [range] 8.7 g/L [4.1-14.5 g/L]
vs 11.2 g/L [0.6-28 g/L], P , .0001), these decreased levels
persisted through the ﬁrst year. At 2 years’ follow-up, there was no
difference in IgG levels from baseline values. A signiﬁcant decrease
in IgM levels following RTX treatment persisted even 2 years after
treatment, with baseline median [range] 0.9 g/L [0.3-8.4 g/L] vs
at 2 years 0.7 g/L [0.1-4.9 g/L], P 5 .0014. Levels of IgA also
decreased slightly but signiﬁcantly with median [range] values after
2 years 2 g/L [0.3-4.5 g/L] vs baseline 2.4 g/L [0.1-8.4 g/L],P5 .034.
In the DXM group, IgG values decreased from baseline median
[range] 11 g/L [2.4-17.4 g/L vs after 2 years 9.5 g/L [7.3-13.4 g/L],
P 5 .0048, as did levels of IgA (baseline median [range] 2.0 g/L
[0.3-5.7 g/L] vs after 1 year 1.7 g/L [0.2-5 g/L], P 5 .0015). No
changes in IgM were found in the DXM group.
Discussion
We present the ﬁrst results from a prospective study on the
largest cohort to date of newly diagnosed ITP patients treated with
RTX1DXM vs DXM alone. Our ﬁndings suggest that up-front
addition of RTX to DXM in treatment of newly diagnosed ITP
improves outcomes and yields longer sustained response rates than
DXM alone.
Our primary end point was sustained complete or partial response
after 6 months of follow-up, which was reached in 57% in the RTX1
DXM group vs 37% in the DXM group (P 5 .02). Our ﬁndings are
largely in line with those reported by Zaja et al, who found sustained
response rates after 6 months in 63% of 49 patients receiving RTX1
DXM vs 36% of 52 patients treated with DXM alone.8 When
regarding time to relapse over a 4-year follow-up period, we also
found a signiﬁcant difference between the 2 groups favoring RTX1
DXM (Figure 2), although numbers at risk were substantially lower
toward the end of the follow-up period.
Patients with chronic ITP are often observed without treatment,
even when platelet counts are low, because the potential adverse
effects of treatments generally do not match the estimated risk of
bleeding in the individual patients. Thus, 1 of our secondary end
points was time to rescue treatment including prednisolone, IVIG,
splenectomy, or any other second-line treatments. Regarding this end
point, we also found a signiﬁcant difference between the 2 groups in
favor of the group receiving RTX1DXM.
Splenectomy is a recommended second-line therapy for ITP, but
the choice of splenectomy is highly dependent on the preferences
of the hematologist and the patient. In this study, the choice of
splenectomy reﬂected current clinical practice at the individual
treatment facility because no common guidelines were outlined in the
protocol. No differences in splenectomy between the 2 groups were
observed.
Persistent hypogammaglobulinemia following rituximab as mono-
therapy or in combination with methotrexate has been reported
in up to 23% of patients with rheumatoid arthritis.14 There have
also been reports of decreasing serum IgG and IgM levels in
children with ITP treated with rituximab.15 Even though the
rituximab-induced hypogammaglobulinemia has not been associ-
ated with an increased risk of infections,14,15 there are still concerns
about the long-term side effects of rituximab. In concordance with
these previous reports, we found that levels of IgM decreased
signiﬁcantly following RTX treatment and remained decreased
even 2 years after treatment. No changes in serum IgM were found
in patients treated with DXM alone. IgG and IgA levels decreased
after RTX1DXM as well as after DXM monotherapy, but
remained within normal range in both groups. IgG values were
available in 7 of 10 patients reporting infections during or after
RTX1DXM treatment; in 3 of the 7, we found a decrease in IgG
levels following RTX, although none of them had IgG levels
below normal range. The infections reported in these 3 patients
were upper respiratory tract infection, eye infection, and urinary
tract infection.
There were no previously undescribed adverse events reported,
and no signiﬁcant differences in the total number of adverse events
between the 2 groups. There were more serious adverse events in
both groups than reported in the 2 previous studies.8,9 This may to
some extent be ascribed to variations in the grading of adverse
events. The 4 deaths in the cohort all occurred in patients older than
80 years of age, and the deaths were not considered to be treatment-
related by the investigator.
All patients in this study were evaluated with a bone marrow
smear and biopsy, chest radiograph, and abdominal ultrasonography
before inclusion to exclude secondary ITP from the cohort. Patient
outcomes were evaluated by both platelet counts and time to rescue
treatment. Taken together, our ﬁndings show that RTX1DXM is
superior to DXM monotherapy in the treatment of newly diagnosed
ITP. On the basis of these results, we propose that RTX should be
considered early in the treatment course of newly diagnosed ITP
patients, even before splenectomy.
Table 2. Serious adverse events and infections
Parameter RTX1DXM DXM
Total serious adverse events 16 9
Thrombocytopenia (without bleeding) requiring hospitalization 5 0
Bleeding grade 3-4 2 1
Deaths 1* 3†
Fever 2 1
Pain 1 1
Dizziness 1 1
Infusion-related anaphylaxis 1 0
Delayed neutropenia 1 0
Vasculitis 1 0
Cataract 1 0
Hyperglycemia 0 1
Chest pain 0 1
Total reported infections 11 9
Upper respiratory tract 4 1
Topical 4‡ 1§
Oral candida 0 3
Pneumonia 2 2
Urinary tract 1 2
Herpes genitalis 1 1
*84-y-old female deceased from pneumonia and heart failure 33 mo after
inclusion.
†83-y-old female deceased from atrial fibrillation and sepsis 3 wk after inclusion;
80-y-old male deceased in own home 4 d after inclusion, cause unknown; 80-y-old
woman deceased 33 mo after inclusion, cause unknown.
‡Bursitis, otitis, bartholinitis, and eye infection.
§Furunculi.
In both groups, age at the time of inclusion was in the range of 18 to 84 years.
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